TMEM25

Summary

TMEM25 (transmembrane protein 25, HGNC:25890) is a protein-coding gene on chromosome 11q23.3, encoding Transmembrane protein 25 (Q86YD3). In neurons, modulates the degradation of NMDA receptor GRIN2B subunit.

Predicted to be involved in negative regulation of excitatory postsynaptic potential and regulation of protein stability. Predicted to be located in late endosome and lysosome.

Source: NCBI Gene 84866 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 89 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_032780

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25890
Approved symbol	TMEM25
Name	transmembrane protein 25
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14399
Ensembl gene	ENSG00000149582
Ensembl biotype	protein_coding
OMIM	613934
Entrez	84866

Gene structure

Transcript identifiers

Ensembl transcripts: 47 — 32 protein_coding, 7 retained_intron, 6 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000313236, ENST00000354064, ENST00000354284, ENST00000359862, ENST00000411589, ENST00000442938, ENST00000524522, ENST00000524725, ENST00000525118, ENST00000525129, ENST00000525298, ENST00000526853, ENST00000526941, ENST00000526973, ENST00000527267, ENST00000527785, ENST00000528373, ENST00000528934, ENST00000529001, ENST00000529176, ENST00000530423, ENST00000531494, ENST00000532749, ENST00000532762, ENST00000533102, ENST00000533137, ENST00000533587, ENST00000533627, ENST00000533689, ENST00000534181, ENST00000872237, ENST00000872238, ENST00000872239, ENST00000872240, ENST00000872241, ENST00000872242, ENST00000931619, ENST00000931620, ENST00000931621, ENST00000931622, ENST00000931623, ENST00000931624, ENST00000947267, ENST00000947268, ENST00000947269, ENST00000947270, ENST00000947271

RefSeq mRNA: 8 — MANE Select: NM_032780 NM_001144034, NM_001144035, NM_001144036, NM_001144037, NM_001144038, NM_001318755, NM_001318757, NM_032780

CCDS: CCDS44745, CCDS44746, CCDS44747, CCDS44748, CCDS81630, CCDS8398

Canonical transcript exons

ENST00000313236 — 9 exons

Exon	Start	End
ENSE00000991515	118533420	118533551
ENSE00002149476	118531192	118531234
ENSE00002200185	118534507	118535829
ENSE00003522744	118531775	118531871
ENSE00003534732	118534029	118534129
ENSE00003538966	118533857	118533887
ENSE00003611707	118532150	118532461
ENSE00003634356	118532917	118533207
ENSE00003634538	118534266	118534355

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 95.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.4115 / max 72.8318, expressed in 1492 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117010	7.1373	1481
117009	0.1985	86
117012	0.0483	14
117013	0.0169	6
117014	0.0104	4

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	95.49	gold quality
cerebellar hemisphere	UBERON:0002245	95.09	gold quality
cerebellar cortex	UBERON:0002129	94.99	gold quality
cerebellum	UBERON:0002037	94.08	gold quality
right frontal lobe	UBERON:0002810	93.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.07	gold quality
prefrontal cortex	UBERON:0000451	92.57	gold quality
cortical plate	UBERON:0005343	91.64	gold quality
anterior cingulate cortex	UBERON:0009835	91.14	gold quality
nucleus accumbens	UBERON:0001882	91.00	gold quality
adenohypophysis	UBERON:0002196	90.84	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.40	gold quality
pituitary gland	UBERON:0000007	90.25	gold quality
frontal cortex	UBERON:0001870	90.25	gold quality
caudate nucleus	UBERON:0001873	90.20	gold quality
neocortex	UBERON:0001950	90.18	gold quality
right adrenal gland cortex	UBERON:0035827	90.05	gold quality
right adrenal gland	UBERON:0001233	89.94	gold quality
left adrenal gland cortex	UBERON:0035825	89.85	gold quality
left adrenal gland	UBERON:0001234	89.82	gold quality
thoracic aorta	UBERON:0001515	89.74	gold quality
ascending aorta	UBERON:0001496	89.73	gold quality
putamen	UBERON:0001874	89.67	gold quality
descending thoracic aorta	UBERON:0002345	89.43	gold quality
ganglionic eminence	UBERON:0004023	89.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.21	gold quality
hypothalamus	UBERON:0001898	89.13	gold quality
small intestine	UBERON:0002108	88.18	gold quality
islet of Langerhans	UBERON:0000006	88.12	gold quality
adrenal cortex	UBERON:0001235	88.09	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.28
E-GEOD-100618	no	219.68
E-GEOD-99795	no	110.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

63 targeting TMEM25, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-548F-5P	99.78	71.02	3093

Literature-anchored findings (GeneRIF, showing 5)

• TMEM25 may be a useful tumor marker for favorable prognosis in breast cancer. (PMID:19776672)
• TMEM25 hypermethylation might play a significant role in altering expression of this gene in colorectal cancer. (PMID:23324576)
• Human-biased TMEM25 expression promotes expansion of neural progenitor cells to alter cortical structure in the developing brain. (PMID:37846797)
• TMEM25 is a Par3-binding protein that attenuates claudin assembly during tight junction development. (PMID:38177906)
• Multidimensional comprehensive and integrated analysis of the potential function of TMEM25 in renal clear cell carcinoma with low expression status. (PMID:38189809)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000101186
mus_musculus	Tmem25	ENSMUSG00000002032
rattus_norvegicus	Tmem25	ENSRNOG00000014218

Paralogs (16): CD22 (ENSG00000012124), SIGLEC1 (ENSG00000088827), SIGLEC8 (ENSG00000105366), CD33 (ENSG00000105383), SIGLEC6 (ENSG00000105492), MAG (ENSG00000105695), SIGLEC9 (ENSG00000129450), SIGLEC10 (ENSG00000142512), SIGLEC11 (ENSG00000161640), SIGLEC16 (ENSG00000161643), SIGLEC7 (ENSG00000168995), SIGLECL1 (ENSG00000179213), SIGLEC15 (ENSG00000197046), SIGLEC14 (ENSG00000254415), SIGLEC12 (ENSG00000254521), SIGLEC5 (ENSG00000268500)

Protein

Protein identifiers

Transmembrane protein 25 — Q86YD3 (reviewed: Q86YD3)

All UniProt accessions (11): Q86YD3, E9PI73, E9PID6, E9PIE6, E9PIR4, E9PIT4, E9PK43, E9PK88, E9PKP3, H0YC87, H0YD63

UniProt curated annotations — full annotation on UniProt →

Function. In neurons, modulates the degradation of NMDA receptor GRIN2B subunit. Plays a role in the regulation of neuronal excitability.

Subunit / interactions. Interacts with GRIN2B.

Subcellular location. Cell membrane Cell membrane Secreted Secreted Late endosome. Lysosome.

Tissue specificity. Expressed throughout the brain with higher levels in the pyramidal cell layer of the hippocampal CA1 and CA3 regions. Also highly expressed within the hippocampal dentate gyrus region and cerebellum and in scattered neurons in the cerebral cortex.

Isoforms (5)

UniProt ID	Names	Canonical?
Q86YD3-1	1	yes
Q86YD3-2	2
Q86YD3-3	3
Q86YD3-4	4
Q86YD3-5	5

RefSeq proteins (8): NP_001137506, NP_001137507, NP_001137508, NP_001137509, NP_001137510, NP_001305684, NP_001305686, NP_116169* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007110	Ig-like_dom	Domain
IPR013162	CD80_C2-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR042864	TMEM25	Family

Pfam: PF08205

UniProt features (21 total): glycosylation site 5, splice variant 4, sequence variant 2, topological domain 2, signal peptide 1, chain 1, disulfide bond 1, sequence conflict 1, transmembrane region 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86YD3-F1	62.47	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 52–107

Glycosylation sites (5): 175, 192, 205, 106, 162

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 88 (showing top): CAGCTG_AP4_Q5, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL, GOBP_MODULATION_OF_EXCITATORY_POSTSYNAPTIC_POTENTIAL, GOBP_REGULATION_OF_NERVOUS_SYSTEM_PROCESS, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_SYNAPTIC_SIGNALING, GOBP_REGULATION_OF_SYSTEM_PROCESS, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, AP2_Q6_01, GOBP_REGULATION_OF_MEMBRANE_POTENTIAL, E2F1_Q3_01, AAGCACA_MIR218, SMAD4_Q6, DODD_NASOPHARYNGEAL_CARCINOMA_DN

GO Biological Process (2): regulation of protein stability (GO:0031647), negative regulation of excitatory postsynaptic potential (GO:0090394)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): extracellular region (GO:0005576), lysosome (GO:0005764), late endosome (GO:0005770), plasma membrane (GO:0005886), endosome (GO:0005768), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
regulation of biological quality	1
negative regulation of biological process	1
excitatory postsynaptic potential	1
modulation of excitatory postsynaptic potential	1
binding	1
lytic vacuole	1
endosome	1
membrane	1
cell periphery	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

592 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM25	TMEM207	Q6UWW9	650
TMEM25	RTP3	Q9BQQ7	571
TMEM25	TMEM116	Q8NCL8	543
TMEM25	TMEM213	A2RRL7	542
TMEM25	NDC1	Q9BTX1	541
TMEM25	ANKRD13B	Q86YJ7	533
TMEM25	TMEM91	Q6ZNR0	529
TMEM25	CDC50B	Q3MIR4	493
TMEM25	PIP5KL1	Q5T9C9	491
TMEM25	TMEM45A	Q9NWC5	483
TMEM25	TMEM88	Q6PEY1	468
TMEM25	RTN4RL2	Q86UN3	456
TMEM25	PHLDB1	Q86UU1	447
TMEM25	SEZ6L2	Q6UXD5	444
TMEM25	EML1	O00423	440

IntAct

18 interactions, top by confidence:

A	B	Type	Score
LDHC	LDHA	psi-mi:“MI:0914”(association)	0.770
TMEM25	GLRX3	psi-mi:“MI:0915”(physical association)	0.670
GLRX3	TMEM25	psi-mi:“MI:0915”(physical association)	0.670
RABGGTB	TMEM25	psi-mi:“MI:0915”(physical association)	0.560
TMEM25	PCNA	psi-mi:“MI:0915”(physical association)	0.370
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
TMEM25	NME4	psi-mi:“MI:0914”(association)	0.350
ZNF302	DMC1	psi-mi:“MI:0914”(association)	0.350
TMEM25	CRLF1	psi-mi:“MI:0914”(association)	0.350
MAGEB4	PIGR	psi-mi:“MI:0914”(association)	0.350
NUP35	CDK14	psi-mi:“MI:0914”(association)	0.350
RDH11	HK1	psi-mi:“MI:0914”(association)	0.350
TMEM25	ATE1	psi-mi:“MI:0914”(association)	0.350

BioGRID (239): TMEM25 (Two-hybrid), TMEM25 (Two-hybrid), TUBB8 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), GYLTL1B (Affinity Capture-MS), CACNA2D2 (Affinity Capture-MS), CES3 (Affinity Capture-MS), WDR60 (Affinity Capture-MS), ALDH1L2 (Affinity Capture-MS), EHD1 (Affinity Capture-MS), TMEM132A (Affinity Capture-MS), PCSK6 (Affinity Capture-MS), NOMO3 (Affinity Capture-MS), LPCAT4 (Affinity Capture-MS), ENTPD6 (Affinity Capture-MS)

ESM2 similar proteins: A1L3C1, A2RRU4, A6QM06, A6QNS9, F1LQY6, O94827, P29372, P29590, P97260, Q01113, Q02833, Q04841, Q12770, Q13505, Q29RM4, Q32KT5, Q32L49, Q3UGX3, Q4R5F9, Q5BK01, Q5I0I4, Q5MNU5, Q5SQH8, Q66T02, Q69Z89, Q6GQT6, Q6RFZ7, Q6UXT9, Q6ZN54, Q70EL4, Q7Z6G3, Q86WI3, Q86YD3, Q8IW40, Q8N1F8, Q8N531, Q8N9H8, Q8TCX5, Q91ZP9, Q920N2

Diamond homologs: Q86YD3, Q9DCF1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1700 predictions. Top by Δscore:

Variant	Effect	Δscore
11:118532916:G:GA	acceptor_gain	1.0000
11:118532995:T:TA	acceptor_gain	1.0000
11:118533073:T:TA	acceptor_gain	1.0000
11:118533207:GG:G	donor_loss	1.0000
11:118533208:G:C	donor_loss	1.0000
11:118533209:T:G	donor_loss	1.0000
11:118534023:CTGTA:C	acceptor_loss	1.0000
11:118534024:T:TA	acceptor_gain	1.0000
11:118534024:TGTA:T	acceptor_loss	1.0000
11:118534025:GTA:G	acceptor_loss	1.0000
11:118534026:TA:T	acceptor_loss	1.0000
11:118534027:A:AC	acceptor_loss	1.0000
11:118534027:A:AG	acceptor_gain	1.0000
11:118534027:AGT:A	acceptor_gain	1.0000
11:118534028:G:GC	acceptor_gain	1.0000
11:118534028:GT:G	acceptor_gain	1.0000
11:118534028:GTG:G	acceptor_gain	1.0000
11:118534028:GTGA:G	acceptor_gain	1.0000
11:118534028:GTGAC:G	acceptor_gain	1.0000
11:118534125:CAGAG:C	donor_loss	1.0000
11:118534127:G:GT	donor_gain	1.0000
11:118534127:GAG:G	donor_gain	1.0000
11:118534129:GG:G	donor_loss	1.0000
11:118534130:GT:G	donor_loss	1.0000
11:118534131:T:A	donor_loss	1.0000
11:118534260:A:AG	acceptor_gain	1.0000
11:118534261:A:G	acceptor_gain	1.0000
11:118534264:A:AG	acceptor_gain	1.0000
11:118534265:G:GA	acceptor_gain	1.0000
11:118534265:GCA:G	acceptor_gain	1.0000

AlphaMissense

2329 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:118532272:T:A	W65R	0.991
11:118532272:T:C	W65R	0.991
11:118532274:G:C	W65C	0.990
11:118532274:G:T	W65C	0.990
11:118533027:T:A	W165R	0.990
11:118533027:T:C	W165R	0.990
11:118532398:T:A	C107S	0.987
11:118532399:G:C	C107S	0.987
11:118532400:C:G	C107W	0.986
11:118532227:T:C	F50L	0.983
11:118532229:C:A	F50L	0.983
11:118532229:C:G	F50L	0.983
11:118532233:T:A	C52S	0.983
11:118532234:G:C	C52S	0.983
11:118532398:T:C	C107R	0.983
11:118532233:T:C	C52R	0.982
11:118532393:T:C	L105P	0.982
11:118532228:T:G	F50C	0.981
11:118532461:T:C	F128L	0.980
11:118532918:C:A	F128L	0.980
11:118532918:C:G	F128L	0.980
11:118532399:G:A	C107Y	0.979
11:118532228:T:C	F50S	0.978
11:118533029:G:C	W165C	0.978
11:118533029:G:T	W165C	0.978
11:118532235:C:G	C52W	0.976
11:118532234:G:A	C52Y	0.975
11:118532393:T:A	L105H	0.975
11:118533503:A:C	S253R	0.974
11:118533505:C:A	S253R	0.974

dbSNP variants (sampled 300 via entrez): RS1000109082 (11:118533115 C>A,G,T), RS1000451566 (11:118538111 C>A), RS1001194423 (11:118543306 G>A,C), RS1001520528 (11:118531757 C>G,T), RS1001578541 (11:118544165 C>G), RS1002029390 (11:118543735 C>A,T), RS1002246734 (11:118532689 C>A,G), RS1002606265 (11:118534983 G>A,C), RS1002673144 (11:118541318 C>T), RS1002955641 (11:118529377 A>C), RS1003659377 (11:118545439 A>G), RS1003818835 (11:118539704 C>T), RS1004066696 (11:118533677 G>A), RS1004145949 (11:118538779 G>T), RS1004605552 (11:118543099 C>G,T)

Disease associations

OMIM: gene MIM:613934 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression, affects cotreatment	2
Vehicle Emissions	decreases reaction, increases expression, decreases expression, increases abundance	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	decreases reaction, increases expression, decreases expression, increases abundance	2
sotorasib	affects cotreatment, decreases expression	1
bisphenol A	decreases expression	1
beta-lapachone	decreases expression	1
sulforaphane	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
MRK 003	decreases expression	1
NSC 689534	affects binding, decreases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Copper	decreases expression, affects binding	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	affects expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Silicon Dioxide	decreases expression	1
T-2 Toxin	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms